Recently, Junshi biology and coherus Biosciences jointly announced that the two sides will expand the cooperation in the field of tumor immunity reached in 2021. Coherus has started the procedure to exercise the license option of js006 (anti tigit monoclonal antibody independently developed by Junshi Biology) in the United States and Canada. On the premise of complying with applicable laws and meeting the conditions agreed in writing by both parties, coherus will pay Junshi biology a down payment of US $35 million, a milestone payment of up to US $255 million for development, declaration and sales, and a sales share of 18% of the net sales of products. It is expected that the transaction will be completed after the completion of government procedures required by applicable laws.
Tigit (T cell immunoglobulin and ITIM domain) blocking antibody combined with PD-1 / PD-L1 inhibitor shows synergistic antitumor activity potential.
According to a number of preclinical studies, js006 showed excellent binding affinity and strong inhibition of tigit pathway. At present, the clinical trial application of js006 has been approved by China's National Drug Administration (nmpa) and the U.S. Food and Drug Administration (FDA). A clinical study of dose escalation and dose expansion (nct05061628) is ongoing to evaluate the safety, tolerance and pharmacokinetics of js006 monotherapy and combined anti-PD-1 monoclonal antibody treprizumab in patients with advanced solid tumors.
"We are very pleased to further expand our fruitful cooperation with coherus in the field of tumor immunity. On the basis of the previous phased achievements of treprizumab, we will incorporate it into the anti tigit monoclonal antibody js006," said Dr. Li Ning, CEO of Junshi biology. "Following the company's international strategy of" based on China and global layout ", we have carried out a number of multinational R & D projects in China, the United States, Southeast Asia, Europe and other countries and regions, thanks to the close cooperation between Junshi biology and the clinical team in the R & D centers in China and the United States. It is believed that the cooperation with coherus will further strengthen the R & D of our products in the United States and Canada And commercialization. "
Since 2012, Junshi biology has built a rich and complementary product pipeline in the field of tumor immunity, in order to explore the combined treatment of I-O drugs, or immunotherapy with traditional radiotherapy and chemotherapy, anti angiogenesis drugs, cytokine drugs and other therapies, so as to provide patients with better treatment options.
Dr. Yao Sheng, senior vice president of Junshi biology, said: "the combination treatment of anti tigit monoclonal antibody and anti-PD-1 monoclonal antibody is promising, which is expected to increase the response of patients to immunotherapy and expand the range of beneficiaries. We look forward to deepening cooperation with coherus and promoting the development of combination therapy of js006 and treprizumab in different tumor species as soon as possible."
Tigit, as a frontier target in the field of tumor immunotherapy, has shown therapeutic potential in many major tumor types.
Source: sina.com
